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Squamous cell carcinoma (SCC), the most common oral neoplasm
of cats, demonstrates aggressive local invasion and has a poor prognosis. In
humans, mutation of the p53 gene, crucial in cell cycle arrest and induction of
apoptosis in damaged cells, is common in neoplasms. Survivin, an inhibitor of
apoptosis, is frequently overexpressed in many types of human cancer. Studies
suggest that wild-type p53 inhibits survivin expression, while mutated p53 does
not. The purposes of this study included immunohistochemical examination of
survivin and p53 expression in feline oral SCC and determination of a correlation
between p53 mutation and survivin overexpression, as well as comparison with
survival time. Survivin expression was noted in 80% (24/30) of cases, while
43.3% (13/30) of cases were positive for p53.

No statistically significant

correlation was noted between p53 and survivin expression, even when corrected
for age, breed, and sex; and survival time was not affected.
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CHAPTER 1
INTRODUCTION
Squamous cell carcinoma is the most common oral neoplasm of cats. The
majority of these neoplasms demonstrate aggressive local invasion and have a poor
prognosis and long-term survival, despite treatment with surgical excision; radiation; or
chemotherapy.

Similarly, oral squamous cell carcinoma is a common malignant

neoplasm in human medicine and has a poor long-term survival rate. Apoptosis, or
programmed cell death, is a mechanism to maintain tissue homeostasis.

Loss of

apoptotic mechanisms is believed to promote tumorigenesis by augmenting mutations
and contributing to genetic instability. The protein p53 has a crucial role in cell cycle
arrest and induction of apoptosis in damaged cells. Mutation of the p53 gene is the most
common genetic aberration reported in human neoplasia, suggesting that loss of wildtype p53 is an important step in tumor development.

Mutation of p53 may also

contribute to growth of neoplastic cells and resistance to chemotherapy.

Another

mechanism that may result in loss of apoptotic mechanisms in neoplastic cells is
expression of survivin, a recently recognized member of the inhibitor of apoptosis family.
Although present in fetal tissues, survivin is not highly expressed in human terminally
differentiated tissues. Studies in a variety of human neoplasms indicate that increased
survivin expression is often correlated with poorly differentiated neoplastic cells, a more
1

aggressive tumor, poor response to therapy, faster time to recurrence, and shorter survival
time. Several recent studies have found that survivin is overexpressed in human oral and
laryngeal squamous cell carcinomas, particularly those with a poorly differentiated
phenotype, aggressive biological behavior, and those that metastasize.

Survivin

expression was also increased in pre-malignant tissues that advanced to malignant oral
squamous cell carcinoma. There may be a correlation between loss of wild-type p53 and
overexpression of survivin in human neoplasms, as some studies suggest that survivin is
normally suppressed by wild- type p53. Indeed, a correlation between elevated p53
accumulation and high survivin expression was found in one recent study of human
laryngeal squamous cell carcinoma.
The goals of this study were to establish survivin expression and to confirm
mutant-type p53 expression in feline oral squamous cell carcinomas.

In addition,

survivin expression and mutant-type p53 accumulation in tumor cells were assessed to
determine if a relationship exists between loss of wild-type p53 and survivin expression.
Finally, these factors were compared to survival times to ascertain if expression of
survivin or p53 could be used as prognostic indicators in feline oral squamous cell
carcinoma.

2

CHAPTER 2
LITERATURE REVIEW
Feline Oral Squamous Cell Carcinoma
Overview
Squamous cell carcinoma (SCC) is the most common oral neoplasm in cats. No
breed or sex predilection has been identified; however, older cats are more commonly
affected, with the average age reported to be approximately twelve years. The tongue
and gingiva are the most commonly affected sites.1, 2 Less frequently, tumors occur in
the tonsils, palate, and pharynx.1 When gingiva is affected, the neoplasm can invade
underlying structures, such as the mandible, maxilla, or hard palate, and result in
periosteal proliferation.2
Clinical Signs
Cats with oral SCC often present with a facial mass and excessive salivation,
dysphagia, halitosis, or loose teeth. Non-specific signs may include weight loss and
anorexia. Although the duration of clinical signs is variable, most cats have only a short
history of signs;1, 2 but the neoplasm is often advanced at the time of presentation.1

3

Gross Features
Lingual tumors occur on the ventral surface of the tongue, near the frenulum, and
are often ulcerated.2 Although lingual tumors often appear as small, white nodules, they
are frequently more extensive on palpation;1 however, the dorsal aspect of the tongue
typically remains unaffected.2

The mucosa of the mandible and maxilla is also a

common site for oral SCC. Because oral SCC of the mucosa often invades underlying
bone, the mass may appear to be a bony tumor.2 Gingival tumors often have an ulcerated
surface.1 Adjacent teeth may become loose.2
Histologic Features
Oral SCC can be definitively diagnosed by biopsy and histopathology.1,

2

Infralingual tumors are frequently composed of a well-differentiated squamous
epithelium that forms keratin pearls; mitotic figures are frequent. A scirrhous response is
induced by invasion of neoplastic cells into the adjacent soft tissue. Gingival tumors
often invade underlying bone, resulting in bony proliferation and remodeling. Gingival
tumors may have fewer keratin pearls and a lower mitotic rate than lingual tumors.1
However, histologic grading of the tumor is not useful in predicting outcome.2
Metastasis
Oral squamous cell carcinomas in cats do not frequently metastasize. When
metastasis occurs, it is typically via lymphatics to the regional lymph nodes.1 Metastasis
to the lungs is rare.2

4

Etiology
The etiopathogenesis is not well understood, but the ventral distribution of tumors
suggests possible prolonged exposure to carcinogens. Infection, trauma, and impaction
of material may be involved in the development of oral squamous cell carcinoma.1
Although one study suggested a correlation between oral squamous cell carcinoma and
infection with feline immunodeficiency virus,3 all cats were negative for feline
immunodeficiency virus in another study. 4 A recent study suggests several factors may
be associated with increased risk of developing oral squamous cell carcinoma, including
flea collar use, feeding canned food or tuna, and exposure to environmental tobacco
smoke.5
Treatment
Oral squamous cell carcinoma in cats has a poor prognosis, despite the treatment
method employed. Combination therapy for the treatment of squamous cell carcinoma
appears to be most effective.2,

6

However, one study found no significant difference

between treatment modalities and survival time.7 Surgical excision alone results in a one
year survival time of less than 20%.1

Even with radical excision, such as

mandibulectomy or maxillectomy, recurrence is frequent,2 with a median survival time
less than two months.7 Addition of radiation therapy following mandibulectomy in one
report improved the median survival time to fourteen months.8 Other studies have also
found that combination therapy resulted in a somewhat increased survival time.9,

10, 11

However, in one study, radiation therapy failed to result in palliation and had a high rate
of side effects in cats with inoperable oral squamous cell carcinomas.6
5

Use of a

liposomal cisplatin analogue was also ineffective in one study.12

A recent article

suggested that use of the cyclooxygenase inhibitor piroxicam may be beneficial, at least
in some cases of feline oral squamous cell carcinoma.13 Feline oral squamous cell
carcinomas were found to overexpress epidermal growth factor receptor, suggesting that
this may be a beneficial target for therapy.14
Human Oral Squamous Cell Carcinoma
Cats have been suggested as an animal model for human oral squamous cell
carcinoma.15 Oral squamous cell carcinoma occurs frequently in humans and is the tenth
most common malignancy diagnosed in the U.S. Despite advances in treatment, the five
year survival rate remains poor, estimated at 50%.16

Mutations in p53 and

overexpression of survivin occur frequently in human oral squamous cell carcinoma and
appear to be involved in tumorigenesis.
Apoptosis
Overview
Apoptosis, or programmed cell death, is important in maintaining tissue
homeostasis and occurs normally during embryogenesis, as well as in a variety of
pathological conditions.

Apoptosis is a coordinated sequence of events, including

condensation of the nucleus and cytoplasm, blebbing of the plasma membrane, and
packeting of organelles and nuclear particles (apoptotic bodies). Phagocytes or adjacent
cells quickly ingest and degrade these apoptotic bodies. In contrast to necrosis, apoptosis
typically does not incite inflammation or scarring.17, 18
6

The process of apoptosis includes an initiation phase of caspase activation and an
executioner phase that results in caspase-mediated cell death. The initiation phase may
occur along extrinsic or intrinsic pathways. The extrinsic pathway is mediated by cellsurface death receptors, such as Fas. When Fas is bound by its ligand, FasL, the Fas
molecules group to form a binding site for the Fas-associated death domain (FADD).
The death receptor can then bind and activate procaspase-8.

These molecules act

catalytically on one another to form active caspase-8, thus initiating downstream events.
In the intrinsic pathway, increased mitochondrial permeability allows release of
proapoptotic molecules, such as cytochrome c. When cytochrome c is released into the
cytoplasm, it binds apoptosis activating factor-1 (Apaf-1), thus activating procaspase-9.
Activated caspase-9 can then induce a cascade of caspase activation. Other molecules,
such as apoptosis-inducing factor (AIF), are released into the cytoplasm to prevent the
action of inhibitors of apoptosis. Mitochondrial permeability is controlled by the Bcl-2
family of proteins, and the initiation of apoptosis is dependent, in part, on the balance of
these molecules. While members such as Bcl-2 and Bcl-x are antiapoptotic, Bak, Bax,
and Bim are proapoptotic. Both the extrinsic and intrinsic routes of caspase initiation
result in the activation of the executioner caspases, including caspase-3, caspase-6, and
caspase-7. Activated executioner caspases degrade cytoskeletal and nuclear proteins,
causing breakdown of cellular structures.17
Apoptosis in the Development of Neoplasia
Although cells with damaged DNA are normally eliminated by apoptosis, many
cancer cells become resistant to apoptotic mechanisms.19 Resistance to apoptosis is a
7

characteristic feature of neoplastic cells,20 and may contribute to tumor growth,
metastasis, and resistance to therapy.21 The mechanisms of apoptotic resistance that are
the focus of this discussion are mutation of p53 and overexpression of the inhibitor of
apoptosis, survivin.
p53
Overview
Normally p53 functions to arrest cell cycle progression if DNA damage has
occurred, allowing time for DNA repair or inducing apoptosis in severely damaged cells.
In human cancer, however, mutation of the p53 gene is the most commonly reported
genetic alteration, suggesting that loss of p53 function may play an important role in
tumorigenesis and resistance to apoptotic mechanisms. In addition, loss of p53 can result
in an increased growth rate of the tumor and resistance to therapy.
Role of p53 in the Cell Cycle
The cell cycle is divided into the S phase of DNA synthesis, the M phase of
mitosis, and gap phases G1 and G2 that precede synthesis and mitosis, respectively. Nondividing cells remain in G0, a quiescent phase.19

Transitions between phases are

regulated by the cyclin-dependent kinase (CDK) family of protein kinases. Cyclin levels
vary during the cell cycle, causing intermittent activation of CDKs.22
Checkpoints exist at each stage of the cell cycle to ensure that progress through
the cell cycle is orderly and to arrest the cell cycle if DNA damage has occurred.
Checkpoints for DNA damage occur at the G1 to S phase before DNA synthesis and the
8

G2 to M phase after DNA replication. Checkpoints are also present during the S and M
phases. Cell cycle arrest at the G1 to S checkpoint after DNA damage has occurred is
p53-dependent.22 A variety of DNA damage can induce p53 activation, such as doublestrand breaks and increased amounts of DNA repair substrates; hypoxia and other forms
of cellular stress may also activate p53. Although the level of p53 in the cell is normally
low because of its short half-life (approximately 20 minutes),23 the cellular level of p53
rapidly increases after DNA damage has occurred;22 and the half-life is prolonged.23
After p53 is activated, a variety of genes are upregulated to induce cell cycle
arrest, resulting in either DNA repair or apoptosis. Activated p21 inhibits CDKs to
prevent progression of the cell cycle. In addition, p53 induces Gadd45 (growth arrest and
DNA damage inducible gene) for DNA repair. Although p53 can function at the G2 to M
checkpoint, p53-independent mechanisms also exist for this stage.22
The mechanism by which p53 induces apoptosis is not well understood.24
However, in some cells with severely damaged DNA, p53 induces proapoptotic genes,
such as Bax, to initiate apoptosis;22 however, p53-dependent apoptosis can also occur in
the absence of Bax activation. Another mechanism whereby p53 induces apoptosis is
regulation of insulin-like growth factor binding protein 3 (IGF-BP3); other genes that
may be affected by p53 include KILLER/DR5 and FAS/APO1.

Expression of the

antiapoptotic factor Bcl-2 and the proto-oncogene c-myc are also suppressed by wild-type
p53.24
Multiple proteins control p53 upregulation.

Mdm2 (murine double minute)

provides a negative feedback loop for p53; however, the p19 (ARF) protein can bind
Mdm2 to prevent this negative feedback.22
9

p53 and Neoplasia
Originally, p53 was described as an approximately 53 Kd protein that was
believed to be a proto-oncogene.25,

26

However, later studies determined that the p53

examined in the original articles was mutated; wild-type p53 actually inhibits
transformation of cells.27 It is now recognized that p53 is mutated in over half of all
human cancers.28, 29 Loss of tumor suppressor function by p53 can occur in a variety of
ways, as noted by Harris and Hollstein, such as “mutation, chromosomal rearrangement
and nondisjunction, gene conversion, imprinting, or mitotic recombination;” p53 can also
be inactivated by interactions with “cellular proteins or viral oncoproteins”30 that corrupt
the p53 pathway. The majority of mutations are substitutions of single amino acids that
result in a missense protein;28 most of these missense mutations occur in sequences that
code for the DNA-binding region of p53.23 Mutation or inactivation of p53 aids in
tumorigenesis by loss of tumor-suppressor function, inhibition of wild-type p53 function
by mutant p53 in heterozygous cells and may also confer a growth advantage to
neoplastic cells.24 Mutations in p53 may also increase resistance to chemotherapy by the
neoplastic cells.31 Mutated p53 frequently has an extended half-life and accumulates in
the cell; thus, mutated p53 can often be detected with immunohistochemistry.30
p53 in Human Oral Squamous Cell Carcinoma
As with many types of human neoplasia, mutation of p53 occurs in approximately
one-half of oral squamous cell carcinomas29 and is the most commonly reported genetic
aberration in oral cancer.32 Mutations detected by polymerase chain reaction (PCR) have
been reported to occur in 39%33 to 42%34 of cases, while p53 immunohistochemical
10

expression has been stated to occur in 37.8%35 to 70%36 of oral squamous cell carcinoma
cases. In addition, a high rate of expression has been found in lymph nodes with
metastatic disease, ranging from 51.1%35 to 72.7%37 of cases. In contrast, normal oral
tissues have a much lower rate of p53 expression. Normal tissues have been reported to
have no38 to 3%36 p53 positive cells, or be limited to the basal cell layer;39 one study
found that no benign tumors of the head and neck were positive.38

However, in

dysplastic epithelium, p53 immunostaining occurred in the suprabasal layer39 and was
reported at a rate of 52%.36 Those dysplastic lesions with positive p53 expression tended
to advance to carcinoma more quickly than those that were negative.36 These findings
indicate an increase in p53 expression from normal, dysplastic epithelium, to carcinoma
and suggest that alterations in p53 may play a role in cancer development and
progression.
The prognostic significance of p53 mutation or immunohistochemical
overexpression in oral squamous cell carcinoma and squamous cell carcinoma of the head
and neck remains unclear. Multiple studies have found an association between p53
mutation33, 34 or immunohistochemical expression38, 40, 41, 42, 43, 44 and a shorter survival
time. Tumors that were immunohistochemically positive for p53 were also associated
with a shorter disease-free interval35, 36, 41, 45 and higher rate of local recurrence in oral46, 47
or laryngeal carcinoma.48 Expression of p5337, 40 and mutation of the p53 gene34 have
also been found to be associated with metastasis and resistance to chemotherapy45 and
radiation therapy.47 In some cases, p53 had prognostic significance and a correlation
with metastasis only when combined with other factors, such as Bcl-xL, Bax,37 p21,49, 50
and mdm2.49 However, other studies found no statistically significant correlation with
11

p53 immunohistochemical expression and survival,51,

52, 53, 54, 55

recurrence,

51, 53, 56

or

response to treatment.51, 57 These studies found rates of expression of p53 from 46%56 to
78%,55 similar to other studies. One paper reported an improved survival rate in cases
with p53 expression.58 While the prognostic significance of p53 in oral squamous cell
carcinoma remains unclear, the high rate of mutation and immunohistochemical
expression suggests its importance in the development and progression of these tumors.
p53 in Feline Oral Squamous Cell Carcinoma
Studies have evaluated p53 expression in feline tumors, although few have
evaluated the correlation of p53 immunostaining and prognosis. The feline p53 gene has
been sequenced and found to have strong homology with the human sequence (82.1%)59
and sequences in other species.60 Feline sequences shared conserved domains with other
species; at common sites of mutation in human cancer, feline sequences were identical to
the human sequences.60 Immunohistochemical expression of p53 has been found in
feline oral squamous cell carcinoma in 60.0% (3/5)61 to 77.7% (7/9)62 of cases. In one
study examining p53 aberration in feline oral squamous cell carcinoma and its association
with environmental tobacco smoke, 65.2% (15/23) of cases had positive p53 nuclear
staining.

Although not statistically significant, cats that had been exposed to

environmental tobacco smoke were four and a half times more likely to overexpress p53,
and those cats that had been exposed for more than five years were seven times more
likely to overexpress p53.63
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p53 in Other Feline Neoplasms
Multiple studies have detected p53 mutations with PCR in a variety of feline
neoplasms. In a case of squamous cell carcinoma, a base pair deletion resulted in a
frameshift mutation and premature stop codon.64 Mutations were also found in cases of
mammary tumors,64,

65, 66

bladder spindle cell carcinoma,67 fibrosarcoma,64,

67, 68

osteosarcoma,66 lymphosarcoma,69 malignant fibrous histiocytoma,64 and pleomorphic
sarcoma.67 Mutations have been reported in feline vaccine-associated sarcoma;70, 71 and
in one study, p53 gene mutations negatively affected recurrence and survival time.71
Immunohistochemical staining to detect abnormal p53 accumulations has also
been performed in a variety of feline neoplasms. Squamous cell carcinomas had positive
Immunoreactivity,62,

72

including cases in the ear61 and eye.61,

73

Other types of

neoplasms with positive p53 staining included mammary tumors,62,
adenocarcinoma,62

osteosarcoma,62

hemangiosarcoma,62 and

small

72,

74,

numbers

75

of

melanocytic tumors.76 Multiple studies have found cases of feline vaccine-associated
sarcoma to be positive for p53 immunohistochemistry.71, 77, 78, 79 In one study of vaccineassociated sarcomas, p53 staining did not correlate with recurrence or survival time;
however, those cases with cytoplasmic rather than nuclear staining had a shorter time to
recurrence.77
p53 in Neoplasms of Other Domestic Species
Mutations in the p53 gene and accumulations of p53 detected by
immunohistochemistry have been found in a variety of canine neoplasms. The canine
p53 gene has strong homology with the human and murine gene.80 Multiple studies have
13

detected

p53

mutations

in

squamous

cell

carcinoma,

with

PCR81

and

immunohistochemistry.61, 72, 82 Other canine neoplasms that have been reported to have
p53 mutations include mammary adenocarcinomas, detected by PCR83, 84, 85, 86, 87, 88, 89, 90
and immunohistochemistry;82, 91, 92, 93, 94 and intestinal adenocarcinoma,82 transitional cell
carcinoma,82 nasal adenocarcinoma,82 and apocrine gland adenocarcinoma82 determined
by immunohistochemistry. Thyroid carcinoma,95 colon cancer,96 and adenoma of the
circumanal gland97 were positive with PCR. Hemangiosarcoma,82 chondrosarcoma,82
and fibrosarcoma82 were positive with immunohistochemistry; osteosarcoma has been
reported to be positive with both immunohistochemistry98 and PCR.96,

99, 100

Cases of

lymphoma96, 101 and leukemia96 have been reported to be positive with PCR; while one
study found positive immunostaining of lymphomas,82 another study reported that
lymphomas were negative.102 Mast cell tumors have been reported to have positive
immunohistochemistry;82, 103 however, positive staining did not predict survival time.103
Melanomas were reported to be infrequently positive with immunohistochemistry, and
positive staining did not affect survival time.76
In other domestic species, p53 immunoreactivity was found in cases of bovine
and equine squamous cell carcinoma,61,

104

including ocular tumors,73,

105

and ovine

squamous cell carcinoma;104 p53 mutations determined by PCR were also found in
equine squamous cell carcinoma.106 Positive p53 immunoreactivity has been reported in
equine lymphoma.107

While in one study, no p53 staining was detected in bovine

lymphoma,107 another study found frequent p53 mutations in cases of bovine leukemia
virus-induced leukemogenesis.108
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Survivin
Overview
Survivin is a recently described member of the inhibitor of apoptosis family
(IAP). Survivin is an approximately 16.5 Kd protein that contains one baculovirus
inhibitor of apoptosis repeat; unlike other IAP’s, survivin does not contain a carboxyl
terminal RING finger.109 Three splice variants of the survivin gene have been identified:
survivin-ΔEx3, survivin-2B,110 and survivin-3B.111 While the functions of these splice
variants are not well understood, in one experiment, survivin-ΔEx3 maintained its
antiapoptotic potential, while survivin-2B had decreased antiapoptotic capability.110 The
function of survivin-3B appears to differ from survivin, and its expression may not be
associated with the G2/ M phase of the cell cycle.111
Survivin Functions
Survivin is bifunctional, acting as both a regulator of mitosis during cell division
and as an inhibitor of apoptosis.112

The bifunctional capability of survivin is

evolutionarily conserved.113 An additional function of survivin in response to vascular
injury has also been recently identified.114
Survivin Function as a Mitosis Regulator
Evidence suggests that survivin has an important function as a mitotic
regulator.115 Survivin expression is cell cycle dependent, and peak expression occurs
during the G2/ M phase of the cell cycle.116 During cytokinesis, survivin appears to be a
member of the chromosomal passenger complex (CPC)117 and interacts with the other
15

chromosomal passengers, including Aurora B,117, 118, 119, 120, 121 inner centromere protein
(INCENP),117, 118, 119. 120, 121, Borealin,117, 119 and Dasra A and Dasra B.118 The CPC has
an important checkpoint function to ensure correct chromosome segregation and kinesis;
survivin’s functions in the CPC are to direct the location of the CPC and control Aurora
B kinase function.115 The importance of survivin in cell division is demonstrated by the
multiple cell defects that occur in the absence of survivin, including multinucleated cells,
abnormal centrosomes122 and mitotic spindles,122,

123

loss of checkpoint signals,124 and

mislocalization of Aurora B.121
In addition to its association with the CPC, survivin also associates with the
mitotic spindle116,

125

and centrosomes.125 Rosa et al recently suggested that survivin,

independently of Aurora B, has multiple functions throughout the cell cycle, including
regulation of microtubule dynamics and nucleation.126 This model defines the functions
of survivin in multiple sites during cell division, including the mitotic spindle,122, 123, 127
spindle checkpoint,124,

128

midbody,129 nucleation and organization of microtubules,122

and microtubule processes in interphase.126
Survivin Function as an Inhibitor of Apoptosis
While the role of survivin in cell division is well established, the mechanism by
which survivin functions as an inhibitor of apoptosis is less well understood.130 While
some studies postulated that survivin-like baculovirus IAP repeat (BIR) containing
proteins, such as BIR-1 in Caenorhabditis elegans, had functions during cytokinesis but
lacked a cytoprotective effect,131 other survivin homologues such as Bir1p in the yeast
Saccharomyces cerevisiae113 and deterin in Drosophila melanogaster132 do have an
16

antiapoptotic function. In addition, survivin lacks some of the structures of other IAP’s,
such as XIAP.133 Unlike XIAP, which has been shown to directly bind caspase-3 and
caspase-7,134 the association of survivin with caspases is divisive, with reports both that is
does135 and does not133 interact directly with caspases. Instead, survivin apparently must
associate with cofactors, such as hepatitis B virus X interacting protein (HBXIP)136 or
XIAP,137 to have an antiapoptotic function.130 When combined with these molecules,
survivin can interfere with caspase-9, interrupt Apaf-1 binding to the apoptosome, and
prevent XIAP degradation.130 Recent evidence suggests that a mitochondrial pool of
survivin exists that can be rapidly released into the cytosol after cellular stress occurs.
This mitochondrial pool of survivin inhibits caspase-9 activation.138 The cytoprotective
function of survivin is well documented, and its importance as an antiapoptotic protein is
validated by the finding that cells with absent or non-functional survivin have mitotic
defects or undergo rapid apoptosis.130
Survivin Expression in Fetal Tissues
When survivin was first described, a northern blot identified survivin transcripts
in fetal kidney and liver, as well as lung and brain; immunohistochemistry has
demonstrated survivin in fetal kidney, liver, lung, gastrointestinal tract,109, 139 and heart.139
The presence of survivin was also recognized by immunohistochemistry and in situ
hybridization in fetal stratified epithelial stem cells, endocrine cells of the pancreas, and
medulla of the thymus.139
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Survivin Expression in Adult Tissues
In the original description of survivin, no transcripts were identified in adult
human tissues, including peripheral leukocytes, lymph node, spleen, pancreas, kidney,
skeletal muscle, liver, lung, brain, or heart; although, small amounts of mRNA were
identified in adult thymus and placenta.109 Survivin has since been found to be expressed
at a low level in a variety of normal adult human cells.140 In human skin, survivin
expression was detected in basal keratinocytes141 and melanocytes.142 Survivin is also
expressed in human143, 144, 145 and mouse146 hematopoietic progenitor cells, thymocytes,127
T cells,147 and neutrophils.148 Survivin is expressed in vascular endothelium149, 150 and
other proliferative tissues such as the testis,151 endometrium,152 and colonic crypt
epithelium.153
Survivin Expression in Neoplastic Cells
In the initial description of survivin, immunohistochemistry and in situ
hybridization demonstrated survivin expression in all cases of lung adenocarcinoma, lung
squamous cell carcinoma, pancreatic adenocarcinoma, colonic adenocarcinoma, breast
carcinoma, and prostate adenocarcinomas, as well as 55% of high-grade lymphomas
examined.109 Survivin has since been found to be expressed in a wide variety of human
neoplasms.140 The mechanism of increased survivin expression in neoplastic cells is not
well understood. Although it has been suggested that increased survivin correlates with
an increased proliferative activity of neoplastic cells, survivin appears to be overexpressed independently of mitotic index.112, 140 In support of this explanation, survivin
expression in neoplastic cells often exceeds the number of dividing cells that are
18

measured by Ki67 expression.112

However, survivin expression is often positively

correlated with the proliferative index in a variety of tumor types.154, 155, 156, 157, 158, 159, 160,
161, 162, 163, 164, 165, 166, 167, 168, 169, 170

In addition to its association with highly proliferative

neoplastic cells, survivin also contributes to survival of neoplastic cells via its function as
an inhibitor of apoptosis; an inverse relationship between survivin expression and
apoptotic rate has been noted in a variety of neoplasms.156, 158, 160, 164, 167, 171, 172, 173, 174
Not only is survivin frequently associated with neoplastic cells with a high
proliferative rate and low apoptotic index, survivin expression is also correlated with a
poor prognosis in multiple types of neoplasms. In many instances, survivin expression
corresponds to a more aggressive phenotype, shorter disease-free interval, and decreased
overall survival time. However, in some types of cancer, survivin expression appears to
be associated with an improved prognosis. These discrepancies may be the result of
different detection methods, evaluation of nuclear or cytoplasmic expression, and the
presence of survivin splice variants.140
Survivin expression may also negatively impact the prognosis because it can
impart resistance to therapy on neoplastic cells. Overexpression of survivin in a variety
of neoplastic cell lines has been associated with resistance to chemotherapy175, 176, 177, 178,
179, 180, 181, 182, 183

and radiation.184, 185 Clinical resistance to chemotherapy has also been

noted in cases of ovarian carcinoma that have a high level of survivin expression.183
Because survivin is frequently overexpressed in human cancers, is not highly
expressed in normal adult tissues, and because it appears to confer resistance to treatment
on neoplastic cells, survivin has been explored as a potential target for cancer therapy.
Methods that have been investigated to decrease survivin expression or function in
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various cell lines include antisense oligonucleotides, ribozymes, small interfering RNA’s,
dominant negative mutants, and inhibitors of cyclin-dependent kinases.186 The results of
preclinical trials indicate that decreased survivin expression was associated with
decreased tumor growth, increased apoptosis of neoplastic cells, and increased sensitivity
of tumor cells to chemotherapy or radiation.187 In addition, survivin appeared not to be
associated with toxicity in vitro or in vivo in xenograft mouse models.188
Survivin Expression in Human Oral Squamous Cell Carcinoma
Survivin has been found to be overexpressed in human oral, oropharyngeal, and
laryngeal neoplasms in multiple studies utilizing immunohistochemistry, PCR, and
western blotting. With IHC staining for survivin, normal oral epithelial tissues were
negative,189,

190

except for occasional basal and suprabasal cells.191,

192, 193

In contrast,

premalignant lesions, such as leukoplakia189, 194 and epithelial dysplasia,195 demonstrated
rates of survivin expression ranging from 14.2% to 97.0%.189, 194, 195 In one study, the
group of precancerous lesions that did not progress to oral SCC had a low rate of survivin
expression (33%), while the group of precancerous lesions that progressed to
malignancies had a much higher percentage of survivin positive cases (94%).

The

number of survivin positive cells within these cases was also higher.193 In multiple
studies, rates of survivin IHC expression in oral and oropharyngeal SCC have varied but
always exceeded 50% of the cases studied. The percentages of survivin positive cases of
oral SCC have been reported as follows: 50%,191 55.3%,194 56%,190 58%,189 82.7%,192
98%,195 and 100%.193, 196, 197 Quantitative real-time PCR (qRT-PCR) has also identified
survivin transcripts in oral SCC.198
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Survivin expression in oral SCC can often be predictive of tumors with a more
aggressive phenotype or greater likelihood of lymph node metastasis.

Survivin

expression has been noted more frequently in poorly differentiated tumors192,
those with a higher grade of malignancy.190,

199

194

and

A statistically significant increase in

survivin expression has been noted in cases of oral SCC that had lymph node metastasis
compared to those without lymph node metastasis.190,

191, 194

Survivin expression was

also significantly higher in cases of oral SCC with distant metastasis.191 In some studies,
survivin expression in oral SCC has had prognostic significance, although the results are
conflicting. Survivin expression resulted in a statistically significant decrease in survival
time in patients with oral SCC in some studies.192, 195, 197 In one study, overall survivin
expression had an apparent, but statistically insignificant, correlation with shorter
survival times, while those cases with predominantly cytoplasmic rather than nuclear
survivin expression were significantly associated with decreased survival time.198
Survivin mRNA expression in lymph nodes with metastases was also a negative
prognostic factor.200 However, one study found that survivin expression was predictive
of an improved outcome in oral SCC patients following radiation therapy.201
Survivin expression has been reported in 74.6%202 to 98.5%203 of laryngeal SCC.
In both of these studies, survivin expression correlated with poor prognosis,202, 203 and in
one study was also associated with lymph node metastasis.202
Survivin Expression in Veterinary Species
Studies investigating surviving expression in companion animals are limited.
Based on PCR, fetal feline and canine survivin mRNA have close homology with the
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human transcript (Johnson ME, unpublished data). In canine tissues, survivin transcripts
were found in normal adult tissues, including heart, lung, liver, kidney, spleen,
gastrointestinal tract, and testis. The study also found survivin mRNA in three malignant
canine neoplasms.204

In a study of canine mast cell tumors, most of the tumors

demonstrated a low rate of nuclear, cytoplasmic, or mixed expression of survivin;
expression of survivin did not correlate with clinical outcome. In this study in canines, a
canine oral squamous cell carcinoma had diffuse positive staining for survivin, and this
tissue was utilized as the positive control. A small population of lymphoid cells in
multiple tissues also stained; however, no staining was observed in a variety of other
tissues.205 RT-PCR demonstrated survivin transcripts in 2 cases of canine transitional
cell carcinoma; canine testicle was used as the positive control tissue.206 To the author’s
knowledge, no additional information on survivin expression in felines or other domestic
animals has been published.
Correlation of p53 and Survivin
Overview
Evidence indicates that survivin expression is normally suppressed by p53.
However, since p53 mutation occurs commonly in human neoplasms, loss of p53
function may correlate with increased survivin expression and may contribute to the
progression of cancer.
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Role of p53 in the Suppression of Survivin
In various human neoplastic cell lines, both exogenous and endogenous p53
protein resulted in suppression of the survivin gene at the level of transcription207, 208, 209
or protein expression.208 Suppression of the survivin gene occurred independently of cell
cycle arrest208, 209 or p53-induced expression of p21waf1.208 In one study, p53 appeared to
exert a suppressive effect on the survivin gene without direct DNA binding. Instead, the
method of suppression was proposed to be through deacetylation of the promoter region
of the survivin gene.209 However, in another study, wild-type p53 bound directly to the
promoter region of the survivin gene; these authors proposed that a p53-Sin3-HDAC
(histone deacetylase) complex bound the promoter region of the survivin gene and
inhibited E2F binding. This study also suggested that p53 can suppress the survivin gene
indirectly by activation of p21waf1.208
Correlation of p53 and Survivin in Cancer Development
Mutant p53 lacked the ability to suppress activity of the survivin promoter in cell
lines208,

209

and did not bind the survivin gene promoter in vivo,208 suggesting a

correlation between loss of wild-type p53 and overexpression of survivin in the
development of cancer.207,

209

In transgenic mice, keratinocytes that overexpressed

survivin were resistant to UVB-induced apoptosis; loss of p53 further contributed to
resistance to apoptosis. This study proposed that survivin expression in conjunction with
the loss of a p53 allele contributed to the occurrence of skin cancer in human patients.210
Another study found that mutation of p53 in melanocytes led to increased survivin
expression in the development of melanoma.211 In cases of laryngeal squamous cell
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carcinoma, the degree of survivin expression was significantly higher in those cases that
were immunohistochemically positive for mutant p53.203

A relationship between

survivin and p53 expression was also noted in cases of experimentally-induced buccal
pouch squamous cell carcinomas in hamsters.212

Correlations between survivin

expression and mutant p53 have also been noted in cases of human ovarian carcinoma,213
breast cancer,214,

215

gastric carcinoma,216 pancreatic adenocarcinoma,217 and non-small

cell lung cancer.218
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CHAPTER 3
MATERIALS AND METHODS
Cases and Control Tissues
Archived cases of feline oral squamous cell carcinoma from Mississippi State
University College of Veterinary Medicine diagnostic laboratory service were reviewed.
Case data was available for January, 1999, to December, 2000, and July, 2005, to
October, 2007 (because of discontinuity of databases). Cases with tissue that had been
decalcified or had an insufficient quantity of tissue were eliminated. Hematoxylin and
eosin (H&E) stained slides of all cases were reviewed to confirm the diagnosis. Thirty
cases of feline oral squamous cell carcinoma were included in the study. Questionnaires
were submitted to the referring veterinarian concerning treatment, date of death, and
cause of death for the cats included in the study. For control tissue, an adult, neutered
male cat that was humanely euthanized at the local humane society for unrelated reasons
was donated. The cat was necropsied shortly after euthanasia. Tissues from all major
organs and oral tissues were placed in 10% neutral buffered formalin for histologic
evaluation or were fresh frozen. In addition, feline testicles from cats routinely neutered
at the humane society or Mississippi State University College of Veterinary Medicine’s
mobile spay/ neuter service were placed in 10% neutral buffered formalin or were fresh
frozen. A gravid uterus from a female cat undergoing routine ovariohysterectomy was
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donated by a local veterinarian; fetal tissues were placed in 10% neutral buffered
formalin for histologic evaluation or were fresh frozen.

Tissues were fixed for

approximately 24 hours before processing.
Survivin Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues were cut to 5 μm and mounted on
charged microscope slides (Fisher Scientific, Pittsburgh, PA); slides were processed
within 24 hours of being cut. Slides were placed in a 70° C oven overnight. Slides were
then deparaffinized in 3 washes of xylene (Fisher Scientific, Pittsburgh, PA) for 5
minutes each and rehydrated in graded ethanols (3 washes of 100% ethanol, 2 washes of
95% ethanol, and 1 wash of 80% ethanol). Slides were then rinsed in distilled water for 5
minutes. Target retrieval was performed by immersing slides in target retrieval solution
(Dako, Carpinteria, CA) and placing them in a steam cooker (Black and Decker, Hunt
Valley, MD) for 20 minutes. Slides were then allowed to cool in the target retrieval
buffer for 20 minutes at room temperature and rinsed in distilled water for 1 minute and
Tris buffered saline (Dako, Carpinteria, CA) for 1 minute. Slides were placed on an
autostainer (model S3400, Dako, Carpinteria, CA). All of the steps were performed at
room temperature; rinsing was performed between each step on the autostainer.
Endogenous peroxidase activity was blocked by covering slides with peroxidase blocking
reagent (Dako, Carpinteria, CA) for 5 minutes; slides were then covered with universal
protein block (Dako, Carpinteria, CA) for 20 minutes. Slides were incubated for 45
minutes with a rabbit anti-human polyclonal survivin antibody (LifeSpan Biosciences,
Seattle, WA) at a dilution of 1:800 in antibody diluent (Dako, Carpinteria, CA). Slides
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were then incubated with a biotinylated anti-rabbit, anti-mouse link, using the LSAB2
HRP system (Dako, Carpinteria, CA) for 30 minutes, followed by streptavidin HRP
(Dako, Carpinteria, CA) for 30 minutes.

Slides were developed with 3,3’-

diaminobenzidene (DAB) chromagen (Dako, Carpinteria, CA) for 10 minutes and
counterstained with hematoxylin (Sigma-Aldrich, St. Louis, MO) for 2 minutes. After
being removed from the autostainer and rinsed in distilled water for 1 minute, slides were
counterstained with bluing solution for 10 seconds and rinsed with distilled water for 1
minute.

Slides were dehydrated in serial ethanols and xylene (Fisher Scientific,

Pittsburgh, PA) and then coverslipped.
Sections of donated feline fetus and feline testicle served as positive controls.
Sections of donated feline brain and skeletal muscle were used as negative controls. An
additional negative control was performed by incubating slides of feline fetus and feline
testicle in a non-relevant antibody (Dako, Carpinteria, CA).
p53 Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues were cut to 5 μm and mounted on
charged microscope slides (Fisher Scientific, Pittsburgh, PA).

Tissues were cut

sequentially and were processed within 24 hours of being cut. Slides were placed in a
70° C oven overnight. Slides were then deparaffinized in 3 washes of xylene (Fisher
Scientific, Pittsburgh, PA) for 5 minutes each and rehydrated in graded ethanols (3
washes of 100% ethanol, 2 washes of 95% ethanol, and 1 wash of 80% ethanol). Slides
were then rinsed in distilled water for 5 minutes. Endogenous peroxidase activity was
blocked by placing slides in a peroxidase blocker (Peroxidazed 1, Biocare Medical,
27

Concord, CA) for 5 minutes. For target retrieval, slides were immersed in a target
retrieval solution (Reveal, Biocare Medical, Concord, CA) and placed in a decloaking
chamber (Biocare Medical, Concord, CA) for 30 minutes. Slides then remained in the
retrieval solution at room temperature for 20 minutes and were rinsed in 2 washes of
distilled water for 3 minutes each. Slides were next placed on an autostainer (Dako,
Carpinteria, CA); the steps were performed at room temperature with rinses between each
step. Avidin and biotin blocking solutions (Biocare Medical, Concord, CA) were placed
on the slides for 10 minutes each. A universal blocking agent (Background Sniper,
Biocare Medical, Concord, CA) was applied to the slides for 15 minutes. Slides were
then incubated with a rabbit anti-human polyclonal (CM1) p53 antibody (Biocare
Medical, Concord, CA) diluted to 1:100 in van Gogh yellow (Biocare Medical, Concord,
CA) for 30 minutes. Slides were next incubated with a biotinylated anti-rabbit, antimouse link using the LSAB2 HRP system (Dako, Carpinteria, CA) for 10 minutes,
followed by streptavidin HRP (Dako, Carpinteria, CA) for 10 minutes. Slides were
developed with 3,3’-diaminobenzidene (DAB) chromagen (Dako, Carpinteria, CA) for 5
minutes and counterstained with hematoxylin (Sigma-Aldrich, St. Louis, MO) for 2
minutes. After being removed from the autostainer and rinsed in distilled water for 1
minute, slides were counterstained with bluing solution for 10 seconds and rinsed with
distilled water for 1 minute. Slides were dehydrated in serial ethanols and xylene (Fisher
Scientific, Pittsburgh, PA), then coverslipped.
A commercially purchased human breast carcinoma slide (Newcomer Supply,
Middleton, WI) served as a positive control. Normal adult feline skin and oral mucosa
from the donated cat served as negative controls. An additional negative control was a
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human breast carcinoma slide incubated with a non-relevant antibody (Dako, Carpinteria,
CA).
Slide Interpretation
For both survivin and p53 immunohistochemistry, the slides were reviewed
independently by two pathologists (HR and MJ) without knowledge of the survival data
or results of the other immunohistochemical stain; when the score of a slide differed, the
case was reviewed and a consensus score was reached. Tissues with fewer than 10%
positive cells were considered negative.

Cases with 10-50% positive cells were

considered moderately positive, while those with greater than 50% positive cells were
considered strongly positive.
Statistical analysis
SAS (Cary, NC) statistical analysis software was utilized in this study.

A

weighted kappa agreement test was performed to measure the degree of agreement
between the immunohistochemical scores assigned by each pathologist (HR and MJ).
The Cochran-Mantel-Haenszel test (Modified Ridit) was utilized to determine if a
correlation existed between p53 mutation and survivin expression, as well as to correct
for age, breed, sex, and neuter status. The Cox proportional hazard test was used in
evaluation of p53 expression and survivin expression in relation to survival time.
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CHAPTER 4
RESULTS
Case Data
Thirty cases of feline oral squamous cell carcinoma were included in this
retrospective study (Table 1). The age was known for 28 cats; the average age was 13.3
years (median 13.5 years; range 7-18 years). The sex was known for all of the cases; 16
were neutered males, 3 were intact males, 6 were spayed females, and 5 were intact
females.

Twenty-six of the cats were domestic shorthairs, and 2 were domestic

longhairs; the breed was not reported for 2 cases. Tumors were reported in a variety of
locations within the oral cavity. Nine tumors were located in the tongue or sublingual
region; 9 were in the mandible or maxilla. Eight of the tumors were in an unspecified site
within the oral cavity. One case each was reported in the pharynx, palatoglossal arch,
gingiva of the left commissure, and hard palate. One case included a section of regional
lymph node (case 14).
Questionnaires concerning date and cause of death were returned for 15 of the
cases. Of 14 cases, the average survival time was 34.6 days (median 31 days; range 0- 69
days). Four of the cats received palliative therapy; surgical debulking was reported in 2
cases. Additionally, in one case, the tumor was surgically debulked, and the cat was
treated with a non-steroidal anti-inflammatory; the cat was still alive 126 days after
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diagnosis. Twelve of the cats were euthanized because of the oral neoplasm, and 1 cat
died naturally from the neoplasm. The cause of death was not reported for 1 case. In
addition, 1 cat was euthanized and 1 cat had a natural death related to the neoplasm;
however, the date of death was not reported for these cases. One cat was reportedly
feline immunodeficiency virus positive (case 4).
Survivin Immunohistochemistry
Eighty percent (24/ 30) of the cases of feline oral squamous cell carcinoma were
positive for survivin with immunohistochemistry (Figure 1); of these, 13 (43.3%) were
moderately positive, and 11 (36.7%) were strongly positive. In the majority of the cases,
immunohistochemical staining was limited to the cytoplasm; however, in 5 cases (cases
13, 18, 19, 26, 28), moderate nuclear staining was also noted (Figure 2). Mitotic figures
were frequently positive (Figure 1), even in those cases that were considered survivin
negative. In sections of the tumors, the surrounding stroma and inflammatory cells were
often negative, but occasionally demonstrated mild cytoplasmic staining. Sections of
lymph node from case 14 contained survivin-positive neoplastic cells (Figure 3). Six
(20%) cases were negative (Figure 4). Multiple cell types in sections of feline fetus had
strong cytoplasmic staining (Figure 5). In sections of feline testicle, seminiferous tubular
epithelium was strongly positive, while the supporting stroma was negative (Figure 6).
Sections of adult feline brain were largely negative (Figure 7), with occasional mild
background staining; sections of adult feline skeletal muscle were negative (Figure 8).
Sections of feline fetus (Figure 9) and testicle (Figure 10) processed with an irrelevant
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control antibody were diffusely negative. The weighted kappa agreement between the
two pathologist’s scores was 0.83 (p <.0001).
p53 Immunohistochemistry
Thirteen of thirty cases (43.3%) of cases were positive with p53
immunohistochemistry (Figure 11); 4 (13.3%) were moderately positive, and 9 (30%)
were strongly positive. All cases demonstrated a strong nuclear reaction; no background
staining was observed. Sections of lymph node from case 14 contained p53-positive
neoplastic cells (Figure 12). Seventeen cases (56.7%) were negative (Figure 13). Slides
of the purchased human breast carcinoma had a strong nuclear reaction with p53
immunohistochemistry (Figure 14). Sections of normal adult feline skin and oral mucosa
were negative, except for occasional basal cells of the epidermis or mucosa (Figure 15); a
small number of these cells also had cytoplasmic staining with the irrelevant control
antibody (Figure 16).

Sections of the human breast carcinoma processed with the

irrelevant control antibody were diffusely negative (Figure 17). Both pathologists were
in 100% agreement on the scores for the p53 immunohistochemistry.
Statistical Analysis
No significant differences were noted between p53 mutation and degree of
survivin overexpression. No statistically significant difference was determined between
p53 and survivin when corrected for age, breed, sex, or neuter status.

The

immunohistochemical scores for p53 and survivin also had no statistically significant
effect on survival time.
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Table 1
Case signalment, survival time, survivin score, and p53 score.
Case Age
(years)
1
8
2
16
3
10
4
11
5
14
6
14
7
17
8
14
9
12
10
11
11
N/R
12
N/R
13
15
14
11
15
13
16
17
17
14
18
11
19
14
20
11
21
15
22
7
23
14
24
7
25
13
26
18
27
13
28
17
29
12
30
17

Sex

Breed Mass Location

MN
F
F
MN
MN
MN
FS
FS
F
MN
M
F
MN
MN
MN
FS
MN
MN
MN
FS
MN
MN
F
M
MN
MN
MN
FS
M
FS

DLH
N/R
DSH
DSH
DSH
DLH
DSH
DSH
N/R
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH
DSH

Oral
Palatoglossal arch
Tongue/ sublingual
Commissure
Tongue/ sublingual
Oral
Oral
Oral
Tongue/ sublingual
Pharyngeal
Tongue/ sublingual
Tongue/ sublingual
Mandible/ maxilla
Mandible/ maxilla
Oral
Mandible/ maxilla
Tongue/ sublingual
Tongue/ sublingual
Mandible/ maxilla
Mandible/ maxilla
Mandible/ maxilla
Hard palate
Mandible/ maxilla
Oral
Oral
Mandible/ maxilla
Tongue/ sublingual
Tongue/ sublingual
Mandible/ maxilla
Oral

Survival
time (days)

0
69
34
28
68
0
3
56
24
26

67
45
24
>126
40

Survivin
score
++
+
++
+
++
+
++
+
+
+
++
++
++
++
+
+
+
+
++
+
+
++
+
++

p53
score
++
+
++
+
+
++
++
+
++
++
++
++
++

N/R: not reported. MN: male neutered; M: intact male; FS: female spayed; F: intact
female. DSH: domestic shorthair; DLH: domestic longhair. Oral: unspecified location.
Survivin and p53 score: (-) <10%; (+) 10-50%; (++) >50%.
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CHAPTER 5
DISCUSSION
In this retrospective study, 30 cases of feline oral SCC were examined for
immunohistochemical expression of p53 and survivin. Slightly less than one-half of
cases were positive with p53 immunohistochemistry, indicating mutation of the p53 gene
in these cases. The majority of cases were positive with survivin immunohistochemistry.
This immunohistochemical staining profile is consistent with reported cases of human
oral SCC, suggesting that cats may potentially serve as a model for the human disease.
However, other mechanisms besides p53 mutation and survivin overexpression may also
contribute to the tumorigenesis of oral SCC.
In human cell lines and in certain cancer types, mutant p53 lacked the ability to
suppress survivin expression, and p53 mutation was significantly associated with
increased survivin expression.

No statistically significant differences were noted

between p53 and survivin immunohistochemical staining in these cases of feline oral
SCC. In addition, p53 mutation and survivin overexpression are often associated with a
decreased survival time and poor overall prognosis in human cases of oral SCC. In this
study, no significant differences were noted in survival time when compared with p53 or
survivin immunostaining. However, the number of cases for which survival data was
available was small. In addition, none of the cats received aggressive treatment, such as
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radiation or chemotherapy, and most were euthanized because of the neoplasm. The lack
of extensive treatment and variable time of euthanasia could have contributed to the short
average survival time, making statistical analysis difficult.
However, to the author’s knowledge, there are no published reports of survivin
immunohistochemical staining in feline tissues. Both feline fetus and testicle proved to
be useful positive controls. Survivin immunostaining of feline tissues was reliable, as
evidenced by the strong agreement between the pathologists when scoring the slides.
In future studies, larger numbers of cases with more uniform clinical treatment
would be more ideal for statistical analysis of survival time.

In addition, further

techniques, such as PCR, could be used to identify the presence of p53 gene mutations or
survivin overexpression. Other methods, such as evaluation of proliferative index and
apoptotic index, may aid in further elucidating the role of survivin in tumors of veterinary
species.
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Figure 1
Feline oral SCC, survivin IHC positive.
Cytoplasmic staining of neoplastic cells; mitotic figures positive. Case 30, 40X.

Figure 2
Feline oral SCC, survivin IHC, nuclear staining.
Strong nuclear staining of neoplastic cells. Case 13, 40X.
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Figure 3
Feline lymph node, survivin IHC.
Metastatic squamous cells in lymph node positive. Case 14, 40X.

Figure 4
Feline oral SCC, survivin IHC negative.
Case 25, 40X.
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Figure 5
Feline fetus, survivin IHC.
Multiple fetal tissues positive. 10X.

Figure 6
Feline testicle, survivin IHC.
Cytoplasmic staining in seminiferous tubules. 40X.
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Figure 7
Feline brain, survivin IHC.
No staining. 40X.

Figure 8
Feline skeletal muscle, survivin IHC.
Skeletal muscle negative; blood vessel endothelium positive. 40X.
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Figure 9
Feline fetus, negative control IHC.
No staining. 10X.

Figure 10
Feline testicle, negative control IHC.
No staining. 10X.
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Figure 11
Feline oral SCC, p53 IHC positive.
Nuclear staining of neoplastic cells. Case 5, 40X.

Figure 12
Feline lymph node, p53 IHC.
Metastatic squamous cells in lymph node positive. Case 14, 40X.
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Figure 13
Feline oral SCC, p53 IHC negative.
Case 23, 40X.

Figure 14
Human breast carcinoma, p53 IHC.
Strong nuclear staining of neoplastic cells. 40X.
64

Figure 15
Feline skin, p53 IHC.
Occasional cytoplasmic staining of epithelial cells. 40X.

Figure 16
Feline skin, negative control IHC.
Occasional non-specific staining of epithelial cells. 40X.
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Figure 17
Human breast carcinoma, negative control IHC.
No staining. 40X.
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